A real-world evidence study on clinical and economic outcomes associated with adalimumab (ADA) and vedolizumab (VDZ) as a first-line biologics for patients with Crohn's disease
Latest Information Update: 05 Jul 2021
At a glance
- Drugs Adalimumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 05 Jul 2021 New trial record
- 23 May 2021 Results presented at the Digestive Disease Week 2021